Ingrid Stenstadvold Ross, Secretary-General of the Norwegian Cancer Society, presented the innovation award, accompanied by a prize of NOK 300,000, to the bladder cancer company Photocure.

“Building on our success and expertise, we aim to create a suite of complementary precision diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare community. Currently, we are collaborating with an AI expert company to develop the next-generation AI-enabled blue light cystoscopy,” stated Dan Schneider, President & Chief Executive Officer of Photocure in the company’s press release.

Proven benefit to the patient

During the award ceremony, Stenstadvoll Ross emphasized how Photocure had established itself as a leading player in Europe and the United States in the field of bladder cancer, bringing products to market and continuing to drive innovation through research and development, reports Oslo Cancer Cluster. The proven benefit to the patient was a key factor in the committee’s decision they stated.

“We are immensely proud that our ongoing innovative work in bladder cancer diagnostics has been recognized on such a prominent platform. As advancements in pharmaceutical therapies for bladder cancer – including immune and gene therapies – continue to transform patient care, the need for precise diagnostics becomes even more critical. Photocure remains dedicated to delivering innovative solutions that help select the right treatment for each patient, and monitor for relapse and treatment response, and ultimately, improve outcomes in uro-oncology,” stated Anders Neijber, Chief Medical Officer of Photocure, in the company’s press release.